BPA Banned in Baby Bottles, Sippy Cups by FDA

The FDA announced this week that the plastic additive Bisphenol-A, which is most commonly known as BPA, may no longer used in baby bottles and sippy cups, contradicting a prior stance by the agency that suggested the amounts of the chemical released by consumer products did not pose a danger. 

The BPA ban was finalized and published by the FDA in the Federal Register on July 17, calling for all all polycarbonate (PC) resins to no longer be used “in infant feeding bottles (baby bottles) and spill-proof cups, including their closures and lids.”

Polycarbonate resins are a combination of BPA and carbonyl chloride or diphenyl carbonate. The chemicals are used to make the plastic harder or shatter proof. However, several studies have suggested that exposure to the chemical, especially among babies or young children, can have severe long-term health consequences.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

In addition to formalizing the ban on BPA in baby bottles and cups, the FDA also proposed another rule the same day, seeking to ban BPA from use in the packaging of infant formula products as well. There is a 61-day comment period for that rule.

Several local and state governments have already passed legislation banning BPA, and most U.S. manufacturers agreed to no longer manufacture baby bottles and cups that contain BPA in 2009.

The decision, while hailed by some health experts and consumer advocates, came at the behest of the American Chemistry Council (ACC), which made the request of FDA in October after determining that the industry had already stopped using BPA in baby products.

In a press release, the ACC claimed that BPA was considered safe to use in baby products, but that it had pushed for the ban to allay concerns and confusion.

Originally developed as a form of synthetic estrogen, BPA is used in the manufacture of many consumer products, such as bottles, cans, cups and other food containers.

Exposure to BPA is suspected of causing hormonal changes by impacting the human endocrine system. It has been linked to cancer, heart disease, diabetes, obesity and asthma. Some research has suggested that BPA can cause developmental abnormalities and other problems over time in infants and young children.

At the end of March, the FDA determined there was not enough data for the agency to change regulations allowing BPA in food packaging, denying a petition filed by the National Resource Defense Council (NRDC) in 2008 and fulfilling a recent settlement agreement to make a decision on the petition.

BPA bans have also already been enacted in baby bottles in Canada and Europe, and France has banned it from all food packaging.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025
Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025 (Posted yesterday)

A series of four bellwether claims in the baby formula NEC lawsuit MDL will be ready to go before a federal juries in May 2025, August 2025, November 2025 and February 2026 according to a proposed trial schedule agreed upon by both plaintiffs and defendants.

AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California
AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California (Posted 2 days ago)

U.S. JPML has transferred all AngioDynamics port catheter lawsuits to the U.S. District Court for the Southern District of California, for coordinated discovery and pretrial proceedings as part of a federal MDL (multidistrict litigation).